Eric Jonasch, MD, from the The University of Texas MD Anderson Cancer Center, Houston, TX, discusses novel immune-oncology combinations at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. Several abstracts have been presented regarding the concept of immune-oncology agents combined with tyrosine kinase inhibitors, for example, nivolumab plus ipilimumab. This combination has shown a survival advantage to sunitinib, which is the current standard of care. There is the potential for the standard of care to change, however, the toxicity, and the expense of the combination must first be considered.

свернуть